Clarity Pharmaceuticals Ltd (ASX:CU6)
4.400
-0.080 (-1.79%)
Nov 7, 2025, 10:39 AM AEST
Clarity Pharmaceuticals Revenue
In the fiscal year ending June 30, 2025, Clarity Pharmaceuticals had annual revenue of 9.46M AUD, down -17.76%. Clarity Pharmaceuticals had revenue of 4.77M in the half year ending June 30, 2025, with 17.37% growth.
Revenue
9.46M
Revenue Growth
-17.76%
P/S Ratio
176.09
Revenue / Employee
137.14K
Employees
69
Market Cap
1.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 9.46M | -2.04M | -17.76% |
| Jun 30, 2024 | 11.51M | 1.71M | 17.41% |
| Jun 30, 2023 | 9.80M | 3.34M | 51.74% |
| Jun 30, 2022 | 6.46M | 3.26M | 102.06% |
| Jun 30, 2021 | 3.20M | 407.65K | 14.62% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Clarity Pharmaceuticals News
- 23 days ago - Clarity Pharma Co-PSMA Trial Meets Main Goal, Detects More Prostate Cancer Lesions Than Standard One - Nasdaq
- 3 months ago - Greatland Resources, Clarity Pharma headline huge ASX 200 rebalance - The Australian Financial Review
- 3 months ago - Clarity Pharmaceuticals readies mega capital raising - The Australian Financial Review
- 1 year ago - Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK - Business Upturn
- 1 year ago - Indoco Remedies partners with Clarity Pharma to strengthen UK presence - Business Upturn
- 1 year ago - Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO - CEOWORLD magazine
- 1 year ago - Three ASX companies jockeying to be the next biotech winners - The Australian Financial Review